跳至主要内容
临床试验/NCT06013358
NCT06013358招募中不适用

The Efficacy of Donor-derived Cell-free DNA as a Biomarker for Subclinical Antibody-mediated Rejection in de Novo Anti-HLA DSA-positive Recipients Who Maintain Stable Renal Function After Kidney Transplantation

Seoul National University Hospital1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2022年12月26日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
200
试验地点
1
主要终点
diagnostic accuracy of subclinical ABMR

研究概览

简要总结

The objective of this study is to predict subclinical Antibody-Mediated Rejection (ABMR) occurrences in de novo DSA-positive recipients maintaining stable renal function after transplantation. This will be achieved through the measurement of donor-derived cell-free DNA. The utility of donor-derived cell-free DNA will be validated based on histological findings using Receiver Operating Characteristics (ROC) curve analysis.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Recipients aged 18 and above
  • Patients with de novo DSA positivity post-kidney transplantation and stable renal function: De novo HLA DSAs encompass both class I and class II, with Mean Fluorescence Intensity (MFI) greater than
  • Stable renal function is defined as serum creatinine variation of less than 15% compared to the last 6 months.
  • Patients with detected de novo HLA-DSAs but did not undergo histological examinations.

排除标准

  • Multi-organ transplant recipients
  • Recipients with positive preformed DSAs
  • ABO-incompatible transplant recipients
  • Pediatric recipients under 18 years old at the time of transplantation
  • Recipients lost to follow-up observation
  • atients already subjected to histological examinations due to positive De novo HLA-DSAs.

结局指标

主要结局

diagnostic accuracy of subclinical ABMR

时间窗: 10 years within kidney transplantation

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验